GlassScriptPhysician profile
Amit Babubhai Patel
NPI 1609850049
$6,532.13
in general payments reported to CMS, 2019-2025
35 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what 95% of Hospice and Palliative Medicine (Internal Medicine) providers received nationally (typical 2025 total: $77.77).
See the full distribution for Hospice and Palliative Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $508 · 2020: $436 · 2021: $1,004 · 2022: $1,370 · 2023: $1,070 · 2024: $1,030 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,814 · Travel and Lodging: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,814.06 |
| Travel and Lodging | $400.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,502.19 | 2021-2025 | |
| Medtronic, INC. | $1,294.35 | 2021-2025 | Intellis Adaptivestim, Synchromedii |
| Collegium Pharmaceutical, INC. | $679.76 | 2019-2025 | Xtampza, Belbuca, Belbuca |
| Pfizer INC. | $351.25 | 2019-2025 | |
| Allergan, INC. | $303.80 | 2019-2021 | |
| Amgen INC. | $294.34 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $241.37 | 2022 | |
| Boston Scientific Corporation | $198.03 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Biohaven Pharmaceuticals, INC. | $191.96 | 2021 | |
| Spr Therapeutics, INC | $181.90 | 2022 | |
| Galderma Laboratories, L.P. | $127.49 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $112.92 | 2021 | |
| Lilly USA, LLC | $112.46 | 2019-2021 | |
| Coloplast Corp | $110.16 | 2024 | |
| Abbott Laboratories | $92.12 | 2019-2023 | Jot Dx |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $92.12 | 2022 | |
| Curonix LLC | $78.55 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Lundbeck LLC | $67.01 | 2023-2024 | Vyepti |
| Almatica Pharma LLC | $61.59 | 2021-2023 | Gralise |
| Biodelivery Sciences International, INC. | $50.30 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $49.76 | 2022 | |
| Averitas Pharma INC. | $46.00 | 2023 | Qutenza |
| Vertex Pharmaceuticals Incorporated | $45.04 | 2025 | |
| Orexo US, INC. | $34.18 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $31.04 | 2020-2021 | |
| Nevro Corp. | $24.64 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $22.92 | 2019-2020 | |
| Indivior INC. | $22.00 | 2024 | Sublocade |
| Upsher-Smith Laboratories LLC | $19.33 | 2020 | |
| Protega Pharmaceutials INC | $17.86 | 2022 | |
| Scilex Pharmaceuticals INC. | $17.72 | 2019 | |
| Ibsa Pharma INC. | $17.02 | 2023 | Tirosint, Licart |
| Covidien LP | $15.08 | 2019 | |
| Forte Bio-Pharma LLC | $13.87 | 2025 | Prolate, Tanlor, Nalocet |
| Kowa Pharmaceuticals America, INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.